ENFLOCIN 120MGML SOLUTION

Quốc gia: Malaysia

Ngôn ngữ: Tiếng Anh

Nguồn: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Thành phần hoạt chất:

ENROFLOXACIN

Sẵn có từ:

GMS Farming Sdn Bhd

INN (Tên quốc tế):

ENROFLOXACIN

Các đơn vị trong gói:

1 L

Sản xuất bởi:

Dexchem Industries Sdn Bhd

Đặc tính sản phẩm

VETERINARY PACKAGE INSERT
PRODUCT NAME:
ENFLOCIN 120MG/ML
SOLUTION
PRODUCT DESCRIPTION:
Pale yellow to light yellow colour solution, which contains
120mg of Enrofloxacin in 1ml.
PRESERVATIVE:
Benzyl Alcohol - 5 mg/ml
PHARMACODYNAMICS:
Mode of Action
Two
enzymes
essential
in
DNA
replication
and
transcription,
DNA
gyrase
and
topoisomerase IV,
have
been
identified
as
the
molecular
targets
of
fluoroquinolones. They modulate the topological state of
DNA through cleaving
and
resealing reactions.
Initially,
both strands of the DNA double helix are cleaved. Then, a
distant
segment
of
DNA
is
passed
through
this
break
before the strands are resealed. Target inhibition is caused
by noncovalent binding of fluroquinolone molecules to an
intermediate state in this sequence of reactions, in which
DNA is cleaved, but both strands are retained covalently
attached
to
the
enzymes.
Replication
forks
and
translational
complexes
cannot
proceed
beyond
such
enzyme-DNA-fluroquinolone complexes, and inhibition of
DNA and mRNA synthesis triggers events resulting in a
rapid, drug concentration-dependant killing of pathogenic
bacteria.
Antibacterial spectrum
Enrofloxacin
is
active
against
many
Gram-negative
bacteria, against Grampositive bacteria and Mycoplasma
spp. In vitro susceptibility has been shown in strains of (i)
Gram-negative species such as, Pasteurella multocida and
Avibacterium
(Haemophilus)
paragallinarum
and
(ii)
Mycoplasma gallisepticum and Mycoplasma synoviae.
Types and mechanisms of resistance
Resistance to fluoroquinolones has been reported to arise
from five sources, (i) point mutations in the genes encoding
for
DNA
gyrase
and/or
topoisomerase
IV
leading
to
alterations of the respective enzyme, (ii) alterations of drug
permeability
in
Gram-negative
bacteria,
(iii)
efflux
mechanisms,
(Iv)
plasmid
mediated
resistance
and
(v)
gyrase
protecting
proteins.
All
mechanisms
lead
to
a
reduced susceptibility of the bacteria to fluoroquinolones.
Cross-resistance
within
the
fluoroquinolone
class
of
antimicrobials is common.
PHARMACOKI